Skip to main content

Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="23" name="CC Event Nav"]
Low-dose ruxolitinib is an approved therapy for patients with myelofibrosis who have thrombocytopenia, but efficacy may be limited. Evidence from PERSIST-2 indicate pacritinib at full dose may provide additional clinical benefit with a similar safety profile compared with ruxolitinib. Read More ›

Pacritinib is currently under investigation in multiple trials and demonstrated efficacy and safety in patients with advanced myelofibrosis during the study period. Patients who continue pacritinib on a compassionate-use basis show further improvement in clinical outcomes. Read More ›

Patients with myelofibrosis who are refractory to JAK inhibitors often lack effective treatment options that not only manage symptoms but can also reduce disease progression. Navtemadlin may improve disease burden in these patients through disease modification. Read More ›

Durvalumab plus either oleclumab or monalizumab improved overall response rate, progression-free survival, and 10-month progression-free survival in locally advanced, unresectable, stage III NSCLC. Read More ›


The phase 3 CheckMate-743 trial demonstrated survival improvement over 3 years with first-line nivolumab plus ipilimumab for patients with unresectable malignant pleural mesothelioma. Read More ›

Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma. Read More ›

Durvalumab plus standard-of-care chemotherapy and durvalumab with tremelimumab plus standard-of-care chemotherapy were both associated with better progression-free survival compared with standard-of-care chemotherapy alone in the treatment of metastatic NSCLC. Read More ›

Nivolumab plus ipilimumab combined with 2 cycles of chemotherapy for the treatment of advanced NSCLC demonstrates durable efficacy compared with 4 cycles of chemotherapy alone in a 2-year follow-up study. Read More ›

After more than 4 years of follow-up, patients with advanced NSCLC treated with nivolumab plus ipilimumab maintained overall survival rates. Read More ›

Page 5 of 27